PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 155 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $3,000 | 0.0% | 520 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $3,000 | +50.0% | 520 | 0.0% | 0.00% | +100.0% |
| Q1 2019 | $2,000 | 0.0% | 520 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $2,000 | -50.0% | 520 | -16.1% | 0.00% | -50.0% |
| Q3 2018 | $4,000 | -20.0% | 620 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $5,000 | 0.0% | 620 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $5,000 | +25.0% | 620 | 0.0% | 0.00% | +50.0% |
| Q4 2017 | $4,000 | -99.9% | 620 | -32.6% | 0.00% | -50.0% |
| Q3 2017 | $6,771,000 | +8.4% | 920 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $6,247,000 | -21.3% | 920 | 0.0% | 0.00% | -20.0% |
| Q1 2017 | $7,940,000 | +99150.0% | 920 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $8,000 | +60.0% | 920 | 0.0% | 0.01% | +66.7% |
| Q2 2016 | $5,000 | – | 920 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |